U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H6I3NO3
Molecular Weight 556.8623
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACETRIZOIC ACID

SMILES

CC(=O)NC1=C(I)C=C(I)C(C(O)=O)=C1I

InChI

InChIKey=GNOGSFBXBWBTIG-UHFFFAOYSA-N
InChI=1S/C9H6I3NO3/c1-3(14)13-8-5(11)2-4(10)6(7(8)12)9(15)16/h2H,1H3,(H,13,14)(H,15,16)

HIDE SMILES / InChI

Molecular Formula C9H6I3NO3
Molecular Weight 556.8623
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.tabletwise.com/brazil/urografina-solution | https://clinicaltrials.gov/ct2/show/NCT01440712 | https://clinicaltrials.gov/ct2/show/NCT01515696 | https://clinicaltrials.gov/ct2/show/NCT00601809

Acetrizoic acid (trade names Gastrografina, Urografina in Portugal) is a palatable lemon-flavored water-soluble iodinated radiopaque X-ray contrast medium for oral or rectal administration only. Acetrizoic acid is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). The preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. Administration of hypertonic Gastrografin solutions may lead to hypovolemia and hypotension due to fluid loss from the intestine.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Gastrografina

Approved Use

Unknown
Diagnostic
Gastrografina

Approved Use

Unknown
Diagnostic
Gastrografina

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
248 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACETRIZOIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
416 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACETRIZOIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1342 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACETRIZOIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.3 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACETRIZOIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.1%
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACETRIZOIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
TABAC.
1950 Jul-Aug
Patents

Patents

Sample Use Guides

Adult oral dosage may range from 30 to 90 mL (11 to 33 g iodine), depending on the nature of the examination and the size of the patient. For infants and children less than 5 years of age, 30 mL (11 g iodine) are usually adequate; for children 5 to 10 years of age, the suggested dose is 60 mL (22 g iodine).
Route of Administration: Oral
In Vitro Use Guide
Blood was taken from the femoral artery of heparinized dogs (heparin 500 I.U./kg I.V.). Immediately after collection, the blood samples were incubated for 45 sec. at 37 C with the solutions of the ACETRIZOIC ACID;the final concentrations of the contrast media in the incubation medium were 220 mM. This was done by adding to aliquots of whole blood the solutions oЈ contrast media, which were hyperosmolar to plasma (2200 mOsm).
Substance Class Chemical
Created
by admin
on Fri Dec 15 14:59:15 GMT 2023
Edited
by admin
on Fri Dec 15 14:59:15 GMT 2023
Record UNII
24256BQV7M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACETRIZOIC ACID
MART.   MI   WHO-DD  
Common Name English
ACETRIZOATE
Common Name English
ACETRIZOIC ACID [MART.]
Common Name English
3-(ACETYLAMINO)-2,4,6-TRIIODOBENZOIC ACID
Systematic Name English
ACETRIZOIC ACID [MI]
Common Name English
NSC-758681
Code English
BENZOIC ACID, 3-(ACETYLAMINO)-2,4,6-TRIIODO-
Common Name English
UROKONIC ACID
Common Name English
Acetrizoic acid [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-VATC QV08AA07
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
WHO-ATC V08AA07
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
NCI_THESAURUS C390
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID2022549
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201327
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY
ECHA (EC/EINECS)
201-600-7
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY
FDA UNII
24256BQV7M
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY
MERCK INDEX
m994
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
ACETRIZOIC ACID
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY
NCI_THESAURUS
C83516
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY
SMS_ID
100000078808
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY
NSC
758681
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY
PUBCHEM
6806
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY
DRUG BANK
DB09347
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY
DRUG CENTRAL
63
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY
EVMPD
SUB00256MIG
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY
CAS
85-36-9
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY
MESH
D000100
Created by admin on Fri Dec 15 14:59:16 GMT 2023 , Edited by admin on Fri Dec 15 14:59:16 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY